News | Pacemakers | June 01, 2023

Leadless Pacemakers Soon Available for All Patients

International consortium led by Amsterdam UMC has now delivered an improved version of the innovative pacemaker 

International consortium led by Amsterdam UMC has now delivered an improved verson of the innovative pacemaker

Getty Images


June 1, 2023 — Every year more than one million people receive a pacemaker. Until now, leadless versions were only available for 20% of these patients. However, thanks to an international consortium led by Amsterdam UMC, an improved version will soon be available for all patients. The results of this clinical trial are published in the New England Journal of Medicine

Research from Amsterdam UMC has succeeded in further revolutionizing the wireless pacemaker. The improved version can now be placed in both the atrium and the ventricle of the heart. Thanks to this innovation a larger group of patients can be fitted with a wireless pacemaker. 

Ten years ago, Amsterdam UMC laid the foundations for the development of the wireless pacemaker. At the time a huge innovation on the traditional pacemaker, that sits above the skin and reaches the heart muscle with a wire. However, until now, a wireless pacemaker could only be placed in one cavity of the heart, the ventricle. Therefore, it was only suitable for a small proportion of patients with a slow heart rhythm. Now, the aforementioned clinical trial shows that a device can also be implanted in the atrium of the heart. 

Electric Pulses 

Lead researcher Reinoud Knops, professor of electrophysiology at Amsterdam UMC says “Most patients need a pacemaker that works in both the atrium and the ventricle for optimal contraction of the heart. Before now, that wasn't possible as it is very complicated to place two mini pacemakers that can communicate with each other wirelessly. After thorough research and testing, we managed to make it possible. This means that those who need a pacemaker will soon be able to count on a new treatment." 

The new system consists of two pacemakers, one in the atrium and one in the ventricle, which communicate with each other via electrical pulses. These pacemakers were implanted for the first time in 300 people who were then followed for a minimum of three months. The results of this study showed that the treatment is safe, and that the system works well. 

The Size of a Vitamin 

Pacemakers have been a basic treatment for patients with a slow heart rhythm for many years. Traditional pacemakers consist of a subcutaneous box under the collarbone with a wire connected to the heart by a vein. But these cables are fragile and can break, become detached from the heart, or become infected. This can lead to patients having to go back to the hospital for another operation. For this reason, Amsterdam UMC developed a mini pacemaker without a box or wiring ten years ago, which is the size of a vitamin. This is implanted through the vein and placed in its entirety in the heart. 

The Dual Leadless Mini Pacemaker, developed together with Abbott Laboratories is seeking approval CE Mark for use in the EU. This approval is expected at the beginning of 2024. In the US, FDA approval is expected in the third quarter of 2023. 

For more information: https://www.amsterdamumc.org/en


Related Content

News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
News | Heart Failure

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
Subscribe Now